120 related articles for article (PubMed ID: 18419355)
1. Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment.
Cooper DA; Emery S; Cordery DV
J Infect Dis; 2008 Mar; 197(5):775; author reply 775-6. PubMed ID: 18419355
[No Abstract] [Full Text] [Related]
2. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
3. The impact of antiretroviral therapy on AIDS and survival.
Lundgren JD; Mocroft A
J HIV Ther; 2006 Jun; 11(2):36-8. PubMed ID: 16981594
[No Abstract] [Full Text] [Related]
4. Treatment of AIDS.
Kharkar RD
J Indian Med Assoc; 2002 Mar; 100(3):203. PubMed ID: 12408288
[No Abstract] [Full Text] [Related]
5. Survival time of AIDS patients in Bamrasnaradura Institute.
Chaovavanich A; Chottanapund S; Ausavapipit J; Adulyawat N; Ubonsai W
J Med Assoc Thai; 2006 Nov; 89(11):1859-63. PubMed ID: 17205866
[TBL] [Abstract][Full Text] [Related]
6. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
[TBL] [Abstract][Full Text] [Related]
7. When to start antiretroviral therapy--ready when you are?
Sax PE; Baden LR
N Engl J Med; 2009 Apr; 360(18):1897-9. PubMed ID: 19339713
[No Abstract] [Full Text] [Related]
8. Acyclovir controversy.
Torres G
GMHC Treat Issues; 1995 Apr; 9(4):3-4. PubMed ID: 11362365
[TBL] [Abstract][Full Text] [Related]
9. [Retroviruses and opportunistic diseases: the catch of intermittent treatments?].
Nau JY
Rev Med Suisse; 2006 Feb; 2(54):553. PubMed ID: 16562541
[No Abstract] [Full Text] [Related]
10. [Ten years of commitment to persons living with HIV-AIDS: evaluation of the management in three ambulatory treatment centers of the French Red Cross in Africa].
Mouala C; Madec Y; Adam G; Courpotin C; Fikouma V; Gentilini M; Ould Mohamedoune A; Nzounza P; Schaer E; Simon B; Mattei JF
Sante; 2008; 18(2):89-95. PubMed ID: 19188132
[TBL] [Abstract][Full Text] [Related]
11. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
[TBL] [Abstract][Full Text] [Related]
12. Structured treatment interruption for patients with human immunodeficiency virus infection.
Roca B
N Engl J Med; 2003 Dec; 349(23):2268-9; author reply 2268-9. PubMed ID: 14657438
[No Abstract] [Full Text] [Related]
13. Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy.
Garlin AB; Sax PE
Clin Infect Dis; 2005 Nov; 41(9):e83-5. PubMed ID: 16206091
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
15. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa.
Harries AD; Zachariah R; Lawn SD
Int J Tuberc Lung Dis; 2009 Jan; 13(1):6-16. PubMed ID: 19105873
[TBL] [Abstract][Full Text] [Related]
16. HIV, research, ethics and women.
Salvi V; Damania K
J Postgrad Med; 2006; 52(3):161-2. PubMed ID: 16855313
[No Abstract] [Full Text] [Related]
17. FDA workshop on clinical trial design, September 6-7--registration by Aug. 18. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Aug; (no 228):5-6. PubMed ID: 11362627
[TBL] [Abstract][Full Text] [Related]
18. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia.
Thai S; Koole O; Un P; Ros S; De Munter P; Van Damme W; Jacques G; Colebunders R; Lynen L
Trop Med Int Health; 2009 Sep; 14(9):1048-58. PubMed ID: 19573140
[TBL] [Abstract][Full Text] [Related]
19. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
20. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
Podlekareva D; Mocroft A; Kirk O; Reiss P; Aldins P; Katlama C; Kovari H; Stellbrink HJ; D'Arminio Monforte A; Lundgren JD;
Scand J Infect Dis; 2008; 40(11-12):908-13. PubMed ID: 18609197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
